Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy

Mathilde S Larsen; Karsten Bjerre; Anita Giobbie-Hurder; Anne-Vibeke Lænkholm; Katrine L Henriksen; Bent Ejlertsen; Anne Elisabeth Lykkesfeldt; Birgitte B Rasmussen

doi:10.3109/0284186X.2011.653009

Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy

Mathilde S Larsen, Karsten Bjerre, Anita Giobbie-Hurder, Anne-Vibeke Lænkholm, Katrine L Henriksen, Bent Ejlertsen, Anne Elisabeth Lykkesfeldt, Birgitte B Rasmussen

19 Citations (Scopus)

Abstract

Estrogen receptor (ER) status is not an optimal marker for response to adjuvant endocrine therapy since approximately 30% of patients with ER-positive tumors eventually relapse. Bcl-2 is regulated by ER and may thus be considered as an indicator of ER activity and a candidate supplementary marker to ER status.

Original language	English
Journal	Acta Oncologica
Volume	51
Issue number	6
Pages (from-to)	781-9
Number of pages	9
ISSN	0284-186X
DOIs	https://doi.org/10.3109/0284186X.2011.653009
Publication status	Published - 2012

Keywords

Antineoplastic Agents, Hormonal
Breast Neoplasms
Carcinoma, Ductal, Breast
Chemotherapy, Adjuvant
Double-Blind Method
Female
Humans
Immunoenzyme Techniques
In Situ Hybridization, Fluorescence
Middle Aged
Neoplasm Grading
Prognosis
Proto-Oncogene Proteins c-bcl-2
Receptor, erbB-2
Receptors, Estrogen
Retrospective Studies
Survival Rate
Tamoxifen
Tissue Array Analysis

Access to Document

10.3109/0284186X.2011.653009

Cite this

Larsen, M. S., Bjerre, K., Giobbie-Hurder, A., Lænkholm, A.-V., Henriksen, K. L., Ejlertsen, B., Lykkesfeldt, A. E., & Rasmussen, B. B. (2012). Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy. Acta Oncologica, 51(6), 781-9. https://doi.org/10.3109/0284186X.2011.653009

@article{86c006f4794f4d4ab79e88e7bef583d7,

title = "Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy",

abstract = "Estrogen receptor (ER) status is not an optimal marker for response to adjuvant endocrine therapy since approximately 30\% of patients with ER-positive tumors eventually relapse. Bcl-2 is regulated by ER and may thus be considered as an indicator of ER activity and a candidate supplementary marker to ER status.",

keywords = "Antineoplastic Agents, Hormonal, Breast Neoplasms, Carcinoma, Ductal, Breast, Chemotherapy, Adjuvant, Double-Blind Method, Female, Humans, Immunoenzyme Techniques, In Situ Hybridization, Fluorescence, Middle Aged, Neoplasm Grading, Prognosis, Proto-Oncogene Proteins c-bcl-2, Receptor, erbB-2, Receptors, Estrogen, Retrospective Studies, Survival Rate, Tamoxifen, Tissue Array Analysis",

author = "Larsen, \{Mathilde S\} and Karsten Bjerre and Anita Giobbie-Hurder and Anne-Vibeke L{\ae}nkholm and Henriksen, \{Katrine L\} and Bent Ejlertsen and Lykkesfeldt, \{Anne Elisabeth\} and Rasmussen, \{Birgitte B\}",

year = "2012",

doi = "10.3109/0284186X.2011.653009",

language = "English",

volume = "51",

pages = "781--9",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Medical Journals Sweden AB",

number = "6",

}

TY - JOUR

T1 - Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy

AU - Larsen, Mathilde S

AU - Bjerre, Karsten

AU - Giobbie-Hurder, Anita

AU - Lænkholm, Anne-Vibeke

AU - Henriksen, Katrine L

AU - Ejlertsen, Bent

AU - Lykkesfeldt, Anne Elisabeth

AU - Rasmussen, Birgitte B

PY - 2012

Y1 - 2012

N2 - Estrogen receptor (ER) status is not an optimal marker for response to adjuvant endocrine therapy since approximately 30% of patients with ER-positive tumors eventually relapse. Bcl-2 is regulated by ER and may thus be considered as an indicator of ER activity and a candidate supplementary marker to ER status.

AB - Estrogen receptor (ER) status is not an optimal marker for response to adjuvant endocrine therapy since approximately 30% of patients with ER-positive tumors eventually relapse. Bcl-2 is regulated by ER and may thus be considered as an indicator of ER activity and a candidate supplementary marker to ER status.

KW - Antineoplastic Agents, Hormonal

KW - Breast Neoplasms

KW - Carcinoma, Ductal, Breast

KW - Chemotherapy, Adjuvant

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Immunoenzyme Techniques

KW - In Situ Hybridization, Fluorescence

KW - Middle Aged

KW - Neoplasm Grading

KW - Prognosis

KW - Proto-Oncogene Proteins c-bcl-2

KW - Receptor, erbB-2

KW - Receptors, Estrogen

KW - Retrospective Studies

KW - Survival Rate

KW - Tamoxifen

KW - Tissue Array Analysis

UR - https://www.scopus.com/pages/publications/84863864599

U2 - 10.3109/0284186X.2011.653009

DO - 10.3109/0284186X.2011.653009

M3 - Journal article

C2 - 22462654

SN - 0284-186X

VL - 51

SP - 781

EP - 789

JO - Acta Oncologica

JF - Acta Oncologica

IS - 6

ER -

Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this